What Atrium Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 6 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 252,500 |
| Disposed | 0 | 0 |
| Net activity | +0 | +252,500 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hoyos Rocio Martin | Chief Strategy Officer | Apr 20 | Grant / award · A | +30,000 | — | — | 46,660 |
| Kenney Stephanie | See Remarks | Apr 20 | Grant / award · A | +30,000 | — | — | 35,460 |
| Younis Husam | Chief Scientific Officer | Apr 20 | Grant / award · A | +30,000 | — | — | 52,657 |
| Winslow Brendan R. | Chief Financial Officer | Apr 20 | Grant / award · A | +30,000 | — | — | 43,601 |
| Gallagher Kathleen P. | See Remarks | Apr 20 | Grant / award · A | +102,500 | — | — | 131,361 |
| Hughes Steven George | Chief Medical Officer | Apr 20 | Grant / award · A | +30,000 | — | — | 73,097 |
Loading...
